1 March 2016 - The Transparency Commission will consider the reimbursement of daclatasvir dihydrochloride (Daklinza), ustekinumab (Stelara), radium Ra 223 dichloride (Xofigo), pemetrexed disodium heptahydrate (Alimta), cangrelor (Kengrexal), aclidinium bromide with eformoterol fumarate dihydrate (Brimica Genuair/Duaklir Genuair) and cobimetinib hemifumarate (Cotellic).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-02/ordre_du_jour_ct_02032016_internet.pdf [French]